Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Changes to This Summary (10 / 21 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Editorial changes were made to this summary.
Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options by Stage
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.Stage 0 (Papillary Carcinoma and Carcinoma in Situ)Treatment of stage 0 may include the following:Transurethral resection with fulguration.Transurethral resection with fulguration followed by intravesical biologic therapy or chemotherapy.Segmental cystectomy.Radical cystectomy.A clinical trial of photodynamic therapy.A clinical trial of biologic therapy.A clinical trial of chemoprevention therapy given after treatment so the condition will not recur (come back).Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with stage 0 bladder cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of
Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview
Information about the treatment of urethral cancer and the outcomes of therapy is derived from retrospective, single-center case series and represents a very low level of evidence of 3iiiDiv. The majority of this information comes from the small numbers of cases accumulated over many decades at major academic centers. Therefore, the treatment in these reports is usually not standardized and the treatment also spans eras of shifting supportive care practices. Because of the rarity of urethral cancer, its treatment may also reflect extrapolation from the management of other urothelial malignancies, such as bladder cancer in the case of transitional cancers, and anal cancer in the case of squamous cell carcinomas. Role of SurgerySurgery is the mainstay of therapy for urethral cancers in both women and men.[Level of evidence: 3iiiDiv] The surgical approach depends on tumor stage and anatomic location, and tumor grade plays a less important role in treatment decisions.[1,2] Although the
Bladder and Other Urothelial Cancers Screening (PDQ®): Screening - Health Professional Information [NCI] - Overview
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about Bladder and Other Urothelial Cancers screening.
Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (10 / 23 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. This summary was comprehensively reviewed and extensively revised.This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Urethral Cancer Associated With Invasive Bladder Cancer
Approximately 10% (range, 4%–17%) of patients who undergo cystectomy for bladder cancer can be expected to have or to later develop clinical neoplasm of the urethra distal to the urogenital diaphragm. Factors associated with the risk of urethral recurrence after cystectomy include:[1,2]Tumor multiplicity.Papillary pattern.Carcinoma in situ.Tumor location at the bladder neck.Prostatic urethral mucosal or stromal involvement.The benefits of urethrectomy at the time of cystectomy need to be weighed against the morbidity factors, which include added operating time, hemorrhage, and the potential for perineal hernia. Tumors found incidentally on pathologic examination are much more likely to be superficial or in situ in contrast to those that present with clinical symptoms at a later date when the likelihood of invasion within the corporal bodies is high. The former lesions are often curable, and the latter are only rarely so. Indications for urethrectomy in continuity with
Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Bladder Cancer Treatment
The prognosis for any patient with progressive or recurrent invasive bladder cancer is generally poor. Management of recurrence depends on previous therapy, sites of recurrence, and individual patient considerations. Treatment of new superficial or locally invasive tumors that develop in the setting of previous conservative therapy for superficial bladder neoplasia has been discussed earlier in this summary.Recurrent or progressive disease in distant sites or after definitive local therapy has an extremely poor prognosis, and clinical trials should be considered whenever possible. Patients who have not received previous chemotherapy for urothelial carcinoma should be considered for chemotherapy as described above for stage IV disease. Palliative radiation therapy should be considered for patients with symptomatic tumors.Standard Treatment Options for Recurrent Bladder CancerStandard treatment options for patients with recurrent bladder cancer include the following:Combination
Bladder and Other Urothelial Cancers Screening (PDQ®): Screening - Health Professional Information [NCI] - Changes to This Summary (02 / 27 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Description of EvidenceAdded text to state that a positive family history of bladder cancer has also been associated with an increased risk of bladder cancer (cited Burger et al. as reference 3).Added Gu et al., Engel et al., and Sanderson et al. as references 8, 10, and 14, respectively.Revised text to state that a variety of industrial exposures have also been implicated as risk factors for developing bladder cancer, primarily aromatic amines, such as 2-naphthylamine, beta-naphthylamine, or 4-chloro-o-toluidine, present in the production of dyes and benzidine and its derivatives; possibly chlorinated aliphatic hydrocarbons; chlorination by-products in treated water; aluminum production (polycyclic aromatic hydrocarbons, fluorides), and certain aldehydes.Revised text to state that
Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Distal Urethral Cancer
Female Distal Urethral CancerIf the malignancy is at or just within the meatus and superficial parameters (stage 0/Tis, Ta), open excision or electroresection and fulguration may be possible. Tumor destruction using Nd:YAG or CO2 laser vaporization-coagulation represents an alternative option. For large lesions and more invasive lesions (stage A and stage B, T1 and T2, respectively), brachytherapy or a combination of brachytherapy and external-beam radiation therapy are alternatives to surgical resection of the distal third of the urethra. Patients with T3 distal urethral lesions, or lesions that recur after treatment with local excision or radiation therapy, require anterior exenteration and urinary diversion. If inguinal nodes are palpable, frozen section confirmation of tumor should be obtained. If positive for malignancy, ipsilateral node dissection is indicated. If no inguinal adenopathy exists, node dissection is not generally performed, and the nodes are followed clinically.